A natural substance isolated from a houseplant shows promise as a potential treatment to prevent and reverse pulmonary hypertension (PH), a study found. Treatment with FR900359 (FR) reversed the disease in a mouse model of PH, and relaxed pulmonary arteries of mice, pigs, and humans. FR activity was equivalent…
News
Reviva Pharmaceuticals has been granted a patent in Europe that covers using brilaroxazine, formerly RP5063, for pulmonary hypertension (PH). The patent covers patients with pulmonary arterial hypertension (PAH) and those who develop PH associated with chronic obstructive pulmonary disease (COPD), an inflammatory lung disorder, or sickle…
Anumana‘s artificial intelligence (AI) algorithm shows promise for the early detection of pulmonary hypertension (PH), a study suggested. The PH Early Detection Algorithm, which analyzes data collected from a routine electrocardiogram (ECG) heart test, was developed by scientists at Anumana, Janssen Research and Development, the Mayo Clinic,…
A global clinical trial evaluating a pulmonary artery denervation (PADN) device in people with pulmonary hypertension (PH) associated with left heart disease has launched in Europe, with the first two patients enrolled at a hospital in Portugal, Pulnovo Medical, the device’s developer, announced. These two adults have undergone…
An advisory committee of the European Medicines Agency (EMA) is recommending that Winrevair (sotatercept) be approved for the treatment of pulmonary arterial hypertension (PAH) in the Europe Union. Specifically, the Committee for Medicinal Products for Human Use (CHMP) issued an opinion recommending that Winrevair to be used in…
A new study identifies the presence of bacteria from the genus Eubacterium fissicatena, known for their pro-inflammatory properties, as a risk factor for pulmonary arterial hypertension (PAH). While the findings suggest “specific intestinal bacteria” are biomarkers for pulmonary PAH, and show “compelling evidence” that connects gut imbalance, or dysbiosis,…
Tempus AI and United Therapeutics are teaming up for a study to advance the use of artificial intelligence (AI) for detecting people at risk of having undiagnosed pulmonary hypertension. “We aim to set a new standard for identifying patients with pulmonary hypertension by getting novel technology into…
The physical activity component of the PAH-SYMPACT — a patient-reported measure of quality of life tailored for people with pulmonary arterial hypertension (PAH) — is an independent predictor of the risk of death among PAH patients, according to a new study from Australia. One unit increase in this parameter…
Direct oral anticoagulants (DOACs) — a type of blood thinner medication — are as safe and effective as vitamin K antagonists (VKAs), the standard blood thinner used to treat chronic thromboembolic pulmonary hypertension (CTEPH), according to a meta-analysis of published studies. The findings support the use of DOACs as a…
A SIRT3 protein deficiency in skeletal muscles, which are attached to bones, was related to pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), a study shows. A lack of SIRT3 triggered the release of LOXL2, a protein that promotes lung tissue scarring, which stimulated the CNPY2…
The amount of normal-looking lung tissue visible on CT scans of the chest can help to predict survival outcomes and response to treatment in people with pulmonary hypertension (PH), a study found. The study, “Significance of normal lung volume on quantitative computed tomography analysis in Group…
Gemcitabine, a chemotherapy given to treat solid cancers, may drive the onset of pulmonary arterial hypertension (PAH) in patients or worsen existing PAH, a recent study reports. Stopping treatment with gemcitabine, with or without a subsequent PAH-approved treatment, led to clinical improvement or disease stabilization for a majority…
